Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab

UBS initiated sum of Jasper Therapeutics connected March 23, 2026, with a Neutral standing and a $1.50 terms target, arguing that contention successful the abstraction could bounds upside. The enactment besides said investors apt privation to spot longer-term durability data, with constricted near-term catalysts, earlier topline information from the BEACON Phase 2b survey successful chronic spontaneous urticaria, oregon CSU, expected successful 2027.

The telephone came aft Jasper had already reported updated information for briquilimab connected January 8. The institution said 67% of further patients treated with briquilimab successful the BEACON Phase 1b/2a survey achieved a implicit effect astatine 12 weeks, portion 83% achieved a implicit effect by week 3 aft the archetypal dose. Jasper besides said the BEACON and open-label hold information were capable to enactment dose enactment for a Phase 2b survey successful CSU planned to statesman successful the 2nd fractional of 2026.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is simply a clinical-stage biotechnology institution processing briquilimab, an antibody therapy targeting KIT (CD117), for mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

While we admit the imaginable of JSPR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.